Lilly sues two compounders over copies of weight-loss drugs
Eli Lilly said on Tuesday it had sued two mass compounders for selling unapproved products that contain tirzepatide, the main ...
Eli Lilly takes actions to stop compounders from making its weight loss med
Eli Lilly ( NYSE: LLY) on Tuesday will file lawsuits against two companies that the drug giant is accusing of mass ...
BioPharma Dive17h
Lilly study data reinforce potential of new kind of heart drug
Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at reducing Lp(a). Whether that will translate to a ...
BioSpace19h
Lilly’s RNA Silencer Lowers Key Cardiovascular Biomarker by Almost 94%
BMO Capital Markets analysts said the results potentially position lepodisiran as “one of the most durable assets in ...
Lilly adds Alzheimer's to online offerings
Eli Lilly on Thursday expanded its direct-to-consumer online platform LillyDirect to include telehealth providers to diagnose ...
WFYI13h
Eli Lilly’s Alzheimer’s drug not recommended by top European regulator
Eli Lilly's Alzheimer's treatment is approved for use in the U.S. but the European Medicines Agency recommended against the ...
Explore more
Eli Lilly’s (LLY) Alzheimer’s Drug Is Rejected in Europe Over Safety Fears
A European health committee has rejected Eli Lilly’s Alzheimer’s drug, Kisunla, because of safety concerns about possible ...
Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors
Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...
Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer
The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...
European committee says Lilly Alzheimer’s drug shouldn’t get marketing approval
A European regulatory committee has rejected Eli Lilly’s U.S.-approved Alzheimer’s disease treatment over potentially ...